<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604629</url>
  </required_header>
  <id_info>
    <org_study_id>REDES-TNF/2012</org_study_id>
    <secondary_id>2011-005871-18</secondary_id>
    <nct_id>NCT01604629</nct_id>
  </id_info>
  <brief_title>Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF</brief_title>
  <acronym>REDES-TNF</acronym>
  <official_title>Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Clinical Pharmacology Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish reumatology Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Clinical Pharmacology Society</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that patients with Spondylarthropathies in
      remission under antiTNF therapy, can maintain the remission with a maintenance dose inferior
      to the currently recommended dose schedule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been shown that the withdrawal of treatment follows with a flare of the disease in a
      short time after the suspension but it has not been evaluated in controlled trials if
      remission could be maintained with a lower dose. A multicenter, national, open-label,
      randomized and controlled clinical trial of 3 years duration (2 years for inclusion + 1 year
      follow-up) is proposed to address this issue. The study will include 190 patients with
      Spondylarthropathies in stable treatment with any single anti-TNF agent and compliance with
      criteria of clinical remission for at least 4 months. Patients will be randomized to
      intervention or control arm, with stratification according to the antiTNF product thet were
      receiving prior to inclusion. Patients will be followed with the calendar of visits
      recommended by the Spanish Society of Rheumatology for clinical practice. The proposed
      hypothesis is of non-inferiority of the experimental arm with dose reduction versus the
      control arm with standard treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who are kept in the acceptable therapeutic objective according Spanish Rheumatology Society (SER) consensus, after one year</measure>
    <time_frame>one year after inclusion</time_frame>
    <description>Proportion of patients who are kept in the acceptable therapeutic objective according Spanish Society of Reumatology (SER) consensus (BASDAI &lt; 4, global clinical impression by physician &lt;4 and by patient &lt; 4 and axial nocturnal pain &lt;4) after one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in remission one year after inclusion in the study</measure>
    <time_frame>one year</time_frame>
    <description>Proportion of patients in remission, defined as ASDAS-C score lower than than 1.3, after one year from inclusion in the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who experience a clinical reactivation</measure>
    <time_frame>last study visit (up to 3 years or December 2014)</time_frame>
    <description>Proportion of patients who experience a clinical reactivation, defined according criteria of active disease by Spanish Society of Reumatology (SER) consensus (BASDAI &gt; 4, global clinical impression by physician &gt;4 and at least one of three following criteria: patient impression &gt;= 4, axial nocturnal pain (VAS) &gt;= 4, and increased of acute phase reactants (reactive C protein (PCR) and/or erytrocyte sedimentation rate (ESR))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who are kept in the acceptable therapeutic objective in the last study visit</measure>
    <time_frame>last study visit (up to 3 years or December 2014)</time_frame>
    <description>Proportion of patients who are kept in the acceptable therapeutic objective according Spanish Society of Reumatology (SER) consensus (BASDAI &lt; 4, global clinical impression by physician &lt;4 and by patient &lt; 4 and axial nocturnal pain &lt;4) in the last study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who are kept in the ideal therapeutic objective in the last follow visit</measure>
    <time_frame>last study visit (up to 3 years or December 2014)</time_frame>
    <description>Proportion of patients who are kept in the ideal therapeutic objective according to the Spanish Society of Reumatology (SER) consensus (BASDAI &lt; 2, global clinical impression by physician &lt;2 and by patient &lt; 2 ) in the last study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical reactivation</measure>
    <time_frame>last study visit (up to 3 years or December 2014)</time_frame>
    <description>Time to clinical reactivation, defined according to the criteria of active disease by Spanish Society of Reumatology (SER) consensus, BASDAI + VAS and ASDAS, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal because of clinical requirement to modify the antiTNF treatment.</measure>
    <time_frame>last study visit (up to 3 years or December 2014)</time_frame>
    <description>Proportion of patients who are withdrawn from the study because of clinical requirement to modify the antiTNF treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NSAIDs use</measure>
    <time_frame>last study visit (up to 3 years or December 2014)</time_frame>
    <description>NSAIDs use measured according semiquantitative Dougados criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suspected Serious Adverse Reactions</measure>
    <time_frame>last study visit (up to 3 years or December 2014)</time_frame>
    <description>Proportion of patients who experience a Serious Adverse Event at least possibly related with anti-TNF therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Suspected Serious Adverse Reaction</measure>
    <time_frame>last study visit (up to 3 years or December 2014)</time_frame>
    <description>Time to Serious Adverse Events at least possibly related with anti-TNF therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in remission after two years from inclusion in the study</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients in remission, defined as ASDAS-C point less than 1.3, after two years from inclusion in the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Spondylarthropathies</condition>
  <arm_group>
    <arm_group_label>Reduced doses of anti-TNF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable doses of anti-TNF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced doses of anti-TNF</intervention_name>
    <description>Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab</description>
    <arm_group_label>Reduced doses of anti-TNF</arm_group_label>
    <other_name>Adalimumab: 40 mg / 3 weeks</other_name>
    <other_name>Etanercept: 50 mg / 10 days</other_name>
    <other_name>Golimumab: 50 mg / 6 weeks</other_name>
    <other_name>Infliximab: 3 mg/kg / 8 weeks</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stable doses of anti-TNF</intervention_name>
    <description>Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis</description>
    <arm_group_label>Stable doses of anti-TNF</arm_group_label>
    <other_name>Adalimumab: 40 mg / 2 weeks</other_name>
    <other_name>Etanercept: 25 mg / 3 days ó 50 mg /7 days</other_name>
    <other_name>Golimumab: 50 mg / 4 weeks</other_name>
    <other_name>Infliximab: 5 mg/kg / 6-8 weeks</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years

          -  Patients with Spondylarthropathies according ASAS group criteria.

          -  Patients under treatment with anti-TNF therapy (infliximab, adalimumab, etanercept,
             golimumab) who present established clinical remission

          -  Patients to give their informed consent to participate in the study

        Exclusion Criteria:

          -  Patients with secondary Spondylarthropathies

          -  Patients with Spondylarthropathies and predominantly clinical of peripheral arthritis
             which receive anti-TNF therapy by peripheral symp tons.

          -  Patients with Spondylarthropathies and other associated diseases that hinders or
             modify the clinical evaluation of the patient (fibromyalgia, chronic inflammatory
             disorders…)

          -  Patients with bowel inflammatory disease

          -  Patients under chronic therapy with anti-TNF therapy who received the patterns of
             reduction that will be explored in the experimental group, or low doses or most spaced
             that those in the experimental group before study inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gratacós Jordi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Sabadell - Corporació Sanitària i Universitaria Parc Taulí UAB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Monte Naranco</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Llerena-Zafra</name>
      <address>
        <city>Llerena</city>
        <state>Badajoz</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan Despí Moisès Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal de Palamós</name>
      <address>
        <city>Palamós</city>
        <state>Girona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Balears</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Móstoles</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic Universitari Sant Joan d'Alacant</name>
      <address>
        <city>Alacant</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMIM-Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Canalejo</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau i Santa Tecla</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Clinical Pharmacology Society</investigator_affiliation>
    <investigator_full_name>Dra. Caridad Pontes</investigator_full_name>
    <investigator_title>Study coordinator</investigator_title>
  </responsible_party>
  <keyword>Spondylarthropathies</keyword>
  <keyword>Persistent clinical remission with anti-TNF therapy</keyword>
  <keyword>Standardized protocol for dose reduction anti-TNF therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

